Allergy Therapeutics leverages major shareholders to enter Latin America
This article was originally published in Scrip
Executive Summary
Allergy Therapeutics is kick-starting its push into Latin America, the "easiest route to reach the emerging markets," by leveraging its major shareholders, the Recalcine Group, Manuel Llobet, the company's CEO, told Scrip.